Emma Essock-Burns1,2, Janine M. Lupo2,
Laleh Jalilian2, Michael D. Prados3, Soonmee Cha2,3,
Susan M. Chang3, Sarah J. Nelson1,4
1UCSF/UCB Joint Graduate
Group in Bioengineering, University of California San Francisco, San
Francisco, CA, United States; 2Department of Radiology &
Biomedical Imaging, University of California San Francisco, San Francisco,
CA, United States; 3Department of Neurological Surgery, University
of California San Francisco, San Francisco, CA, United States; 4Department
of Bioengineering & Therapeutic Sciences, University of California San
Francisco, San Francisco, CA, United States
Antiangiogenic therapy alters the presentation of contrast enhancement limiting the effectiveness of standard assessment methods for evaluating response in GBM patients. Alternate assessment methods are needed, especially for anti-VEGF therapy in the upfront, newly-diagnosed setting. This study tracked volume changes in the DSC-perfusion abnormality, statistically thresholded on a per-patient basis, compared to the standard CE-lesion in 27 GBM patients receiving upfront anti-VEGF therapy. A large, significant decrease in percent recovery abnormality volume was seen by month-1 and decrease in peak height abnormality by month-2. The ultimate goal is to characterize the DSC-perfusion abnormality that best identifies a likely responder patient.
Keywords